High-Value Federal Grants ($5M+) — September 03, 2026

Walgreens won a $290.9 million firm-fixed-price contract from the CDC for specialized medical support, fully obligated and outlayed, providing high revenue certainty through May 2025. The award was made via full and open competition, indicating Walgreens' competitive merit.

The firm-fixed-price structure of the $290.9M Walgreens contract carries cost overrun risk if operational costs exceed estimates, potentially compressing margins.

The contract's future depends on CDC budget allocations for the ICATT program in FY2025 and FY2026; any funding cuts could affect renewal or follow-on awards.

The contract was won via full and open competition, and competitors may bid for future ICATT contracts, potentially eroding Walgreens' market share.

Walgreens could leverage its ICATT contract win to expand its federal healthcare services portfolio, potentially bidding for other CDC or HHS contracts.

The $290.9M CDC contract to Walgreens highlights the government's reliance on private sector expertise for specialized medical support, a growing trend in civilian agencies.

{"entity" => "Walgreens Boots Alliance", "reason" => "Large contract provides revenue visibility but execution and renewal risks remain.", "trigger" => "Q2 2025 earnings call for contract performance updates; FY2025-2026 CDC budget announcements"}

{"entity" => "CDC ICATT Program", "reason" => "Future funding and re-compete decisions will impact Walgreens' contract continuity.", "trigger" => "FY2025 and FY2026 appropriations; any re-compete announcements"}